Yeshan Chen Ai Huang Qin Yang Jing Yu Guiling Li
10.3389/fimmu.2022.987345
Front Immunol
2022 Oct 6;13:987345.
gls-010 endometrial cancer immune checkpoint inhibitors myocarditis re-challenge
CC BY
https://pubmed.ncbi.nlm.nih.gov/36275726/
Antineoplastic Agents, Immunological / adverse effects Endometrial Neoplasms / drug therapy
Antineoplastic Agents, Immunological / adverse effects Endometrial Neoplasms / drug therapy Case Reports Antibodies, Monoclonal B7-H1 Antigen Female Humans Immune Checkpoint Inhibitors / adverse effects Immunologic Factors Neoplasm Recurrence, Local / drug therapy Programmed Cell Death 1 Receptor Programmed Cell Death 1 Receptor Immune Checkpoint Inhibitors Antineoplastic Agents, Immunological B7-H1 Antigen zimberelimab Antibodies, Monoclonal Immunologic Factors
PMC9582132
36275726
Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer
2022